Another new study on inflammatory markers, below [1].
Posted without comment.
"Conclusion:
"The bone metastasis predictive model based on the multiple immune inflammatory parameters (neutrophil-lymphocyte ratio, platelet lymphocyte ratio, lymphocyte/monocyte ratio and albumin/globulin ratio) in prostate cancer patients can reasonably predict the occurrence of bone metastasis and is well worth clinical application."
-Patrick
Thx Patrick. Here is the long version of the study. But I struggle finding the formulas how to calculate the ratios.
Thnaks Patrick. I will definitely study this. Been wonder about those values and how they affect my mets. and bones. probably more important than the PSA to me right now.
My Neutrophils to Lymphocytes ratio was about 2:1 in October 2021. I had not been diagnosed with cancer yet and my BPH symptoms weren’t horrible.
In January 2022 my BPH symptoms got so bad I had urinary retention (couldn’t pee at all). N to L ratio jumped to 10:1 and my ALP started doubling from borderline low to well above normal by the time I was diagnosed with cancer. It is pretty clear in hindsight that that was when my cancer had started metastasizing or really getting a strong presence in my bones.
Over the course of 2022 N:L bounced around from 4:1 to. 6:1 until it started dropping after my first Lupron injection in August. I wasn’t diagnosed with cancer until August. Ranges we’re pretty normal until my chemo started.
After my first chemo in January 2023 the ratio has been about 11:1. I asked the oncologist about it this morning as I’m waiting for my 4th round and she said it’s probably from the dexamethasone they’re giving me at this point.
Inflammation is one of the two primary "drivers" of the sequences and stages of cancer progression, called "The Hallmarks of Cancer". The other driver being genomic instability which is the accelerated accumulation of DNA mutations. It is the continual advance of the "Hallmarks" that leads from carcinoma ion situ (pre-cancer to localized) then to invasive and eventually to treatment resistance ( treatment caused castrate resistance) and also to metastasis.
So the point is not to use inflammatory markers and scores just to predict risk of metastasis. But rather to use them to evaluate how well we are doing to control and reduce systemic inflammation and thus slow down the progression of the cancer. This should be done as early as possible (at BCR if not before). SOC treatments are developed and tested/ approved first in the most advanced cases (mCRPC). So they are not designed to lower the effects of inflammation and genomic instability. PC patients who are not yet fully metastatic and castrate resistant need to be pro-active in this arena IMO.
I have previously posted in greater detail on the Hallmarks of Cancer.
See my reply in pjoshea13's other post today on Systemic Inflammation Score.
MB's Halmarks of Cancer Hall of Fame. Commit it to memory and use it as a framework for action.
Any advice on LU 177?
Consulting on next steps
First BAT cycle results: what next?
